Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Plateau technique de référence
Centre hospitalier universitaire (CHU) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
36 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
144.4 rhumatos / 100 000 hab. — département bien doté
17 publications sur 5 ans
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
21
21 articles ont été cités au moins 21fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
1 679
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
107
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
30
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Université de Bordeaux · Bordeaux Population Health · Hôpital Cardiologique du Haut-Lévêque
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Diet and clinical remission in patients with inflammatory bowel disease: A multicenter cross-sectional study
2025ArticleDigestive and Liver Disease
Risk of incident cancer in patients with Inflammatory Bowel Disease with prior breast cancer: a multicenter cohort study
2025ArticleClinical Gastroenterology and Hepatology
Low serum albumin and severe undernutrition in subjects with diabetes and weight loss
2025ArticleNutrition
Real-world experience of Teduglutide use in adults with short bowel syndrome: a seven-year international multicenter survey
2025ArticleClinical Nutrition
Sa2059 FUTURE OF CHILDREN WITH CHRONIC INTESTINAL FAILURE REACHING ADULTHOOD WITH HOME PARENTERAL NUTRITION. A FRENCH MULTICENTRIC NATION-WIDE STUDY
2024ArticleGastroenterology
Time trend in surgical indications and outcomes in ulcerative colitis—A two decades in-depth retrospective analysis
2023ArticleDigestive and Liver Disease
Prevention of post-operative recurrence of Crohn's disease among patients with prior anti-TNFα failure: A retrospective multicenter study
2023ArticleDigestive and Liver Disease
COVID-19 infection in patients on long-term home parenteral nutrition for chronic intestinal failure
2023ArticleClinical Nutrition ESPEN
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
HOPITAL HAUT-LEVEQUE - CHU
AV DE MAGELLAN, 33604 PESSAC CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Clinical nutrition (Edinburgh, Scotland) · 2018
Journal of Crohn's & colitis · 2021
Abstract Background The approved maintenance regimens for ustekinumab in Crohn’s disease [CD] are 90 mg every 8 or 12 weeks. Some patients will respond partially to ustekinumab or will experience a secondary loss of response. It remains poorly known if these patients may benefit from shortening the interval between injections. Methods All patients with active CD, as defined by Harvey–Bradshaw score ≥ 4 and one objective sign of inflammation [C-reactive protein > 5 mg/L and/or faecal calprotectin > 250 µg/g and/or radiological and/or endoscopic evidence of disease activity] who required ustekinumab dose escalation to 90 mg every 4 weeks for loss of response or incomplete response to ustekinumab 90 mg every 8 weeks were included in this retrospective multicentre cohort study. Results One hundred patients, with a median age of 35 years [interquartile range, 28–49] and median disease duration of 12 [7–20] years were included. Dose intensification was performed after a median of 5.0 [2.8–9.0] months of ustekinumab treatment and was associated with corticosteroids and immunosuppressants in respectively 29% and 27% of cases. Short-term clinical response and clinical remission were observed in respectively 61% and 31% after a median of 2.4 [1.3–3.0] months. After a median follow-up of 8.2 [5.6–12.4] months, 61% of patients were still treated with ustekinumab, and 26% were in steroid-free clinical remission. Among the 39 patients with colonoscopy during follow-up, 14 achieved endoscopic remission [no ulcers]. At the end of follow-up, 27% of patients were hospitalized, and 19% underwent intestinal resection surgery. Adverse events were reported in 12% of patients, including five serious adverse events. Conclusion In this multicentre study, two-thirds of patients recaptured response following treatment intensification with ustekinumab 90 mg every 4 weeks.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
BMC medical ethics · 2024 · Journal Article
Haaser T, Maternowski PJ, Marty S, Duc S, et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2023 · Observational Study
Le Cosquer G, Capirchio L, Rivière P, Denis MA, et al.
Cancers · 2023 · Journal Article
Chappe C, Salut C, Amiot A, Gaye D, et al.
Cancers · 2023 · Journal Article
Poullenot F, Laharie D
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2022 · Journal Article
Amiot A, Laharie D, Malamut G, Serrero M, et al.
Therapeutic advances in gastroenterology · 2022 · Journal Article
Le Cosquer G, Grangeon L, Rivière P, Berger A, et al.
Clinical nutrition ESPEN · 2021 · Journal Article
Pironi L, Steiger E, Joly F, Jeppesen PB, et al.
Clinics and research in hepatology and gastroenterology · 2021 · Journal Article
Tilmant M, Serrero M, Poullenot F, Bouguen G, et al.
Inflammatory bowel diseases · 2020 · Journal Article
Malian A, Rivière P, Bouchard D, Pigot F, et al.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2020 · Journal Article
Pineton de Chambrun G, Amiot A, Bouguen G, Viennot S, et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2019 · Journal Article
Philonenko S, Rivière P, Mallet M, Poullenot F, et al.
International journal of colorectal disease · 2018 · Journal Article
Thicoïpé A, Laharie D, Smith D, Chabrun E, et al.
Clinical nutrition (Edinburgh, Scotland) · 2018 · Journal Article
Pironi L, Konrad D, Brandt C, Joly F, et al.
Inflammatory bowel diseases · 2017 · Letter
Rivière P, Poullenot F, Zerbib F, Laharie D
Inflammatory bowel diseases · 2017 · Comparative Study
Buisson A, Gonzalez F, Poullenot F, Nancey S, et al.
La Revue du praticien · 2014 · English Abstract
Poullenot F, Laharie D
Acta oncologica (Stockholm, Sweden) · 2014 · Case Reports
Poullenot F, Bioulac-Sage P, Laumonier H, Saric J, et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2023 · Multicenter Study
Le Cosquer G, Altwegg R, Rivière P, Bournet B, et al.
Inflammatory bowel diseases · 2023 · Journal Article
Rivière P, Kanters C, Pellet G, Ni A, et al.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025 · Journal Article
Le Cosquer G, Kirchgesner J, Gilletta De Saint Joseph C, Seksik P, et al.
JPEN. Journal of parenteral and enteral nutrition · 2025 · Journal Article
Frezet S, Hermabessière P, Kerlogot L, Wilsius E, et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2016 · Journal Article
Fron C, Pierry C, Poullenot F, Chabrun E, et al.
Clinical nutrition (Edinburgh, Scotland) · 2025 · Published Erratum
Joly F, Jezerski D, Pape UF, Crivelli A, et al.
Alimentary pharmacology & therapeutics · 2025 · Journal Article
Cussac C, Rivière P, Altwegg R, Caillo L, et al.
Clinical nutrition (Edinburgh, Scotland) · 2025 · Journal Article
Joly F, Jezerski D, Pape UF, Crivelli A, et al.
Inflammatory bowel diseases · 2023 · Journal Article
Rivière P, Kanters C, Pellet G, Ni A, et al.
Journal of Crohn's & colitis · 2021 · Journal Article
Fumery M, Peyrin-Biroulet L, Nancey S, Altwegg R, et al.
Alimentary pharmacology & therapeutics · 2025 · Journal Article
Cussac C, Rivière P, Altwegg R, Caillo L, et al.
Frontiers in oncology · 2024 · Journal Article
Eldani C, Kostine M, Faure M, Lazaro E, et al.
JPEN. Journal of parenteral and enteral nutrition · 2022 · Journal Article
Castinel J, Pellet G, Laharie D, Zerbib F, et al.
Nutrients · 2022 · Journal Article
Gotchac J, Poullenot F, Guimber D, Ecochard-Dugelay E, et al.
Nutrients · 2022 · Journal Article
Enaud R, Tetard C, Dupuis R, Laharie D, et al.
Clinical nutrition (Edinburgh, Scotland) · 2026 · Journal Article
Cardenas D, Burgos R, Rothenberg E, Ballmer P, et al.
Journal of Crohn's & colitis · 2025 · Journal Article
Tyrode G, Rivière P, Sebastian S, Poullenot F, et al.
Journal of Crohn's & colitis · 2025 · Journal Article
Tyrode G, Rivière P, Sebastian S, Poullenot F, et al.
sj-tif-1-tag-10.1177_17562848221082879 – Supplemental material for A single dedicated vaccination visit improves vaccination coverage of patients with inflammatory bowel disease
Supplemental material, sj-tif-1-tag-10.1177_17562848221082879 for A single dedicated vaccination visit improves vaccination coverage of patients with inflammatory bowel disease by Guillaume Le Cosquer, Lionel Grangeon, P
sj-tif-2-tag-10.1177_17562848221082879 – Supplemental material for A single dedicated vaccination visit improves vaccination coverage of patients with inflammatory bowel disease
Supplemental material, sj-tif-2-tag-10.1177_17562848221082879 for A single dedicated vaccination visit improves vaccination coverage of patients with inflammatory bowel disease by Guillaume Le Cosquer, Lionel Grangeon, P
A single dedicated vaccination visit improves vaccination coverage of patients with inflammatory bowel disease
Introduction:Patients treated with biologics for inflammatory bowel disease (IBD) have an increased risk of severe infections. Real-life vaccination coverage in this population remains low despite international vaccinati
sj-tif-1-tag-10.1177_17562848221082879 – Supplemental material for A single dedicated vaccination visit improves vaccination coverage of patients with inflammatory bowel disease
Supplemental material, sj-tif-1-tag-10.1177_17562848221082879 for A single dedicated vaccination visit improves vaccination coverage of patients with inflammatory bowel disease by Guillaume Le Cosquer, Lionel Grangeon, P
A single dedicated vaccination visit improves vaccination coverage of patients with inflammatory bowel disease
Introduction:Patients treated with biologics for inflammatory bowel disease (IBD) have an increased risk of severe infections. Real-life vaccination coverage in this population remains low despite international vaccinati
sj-tif-2-tag-10.1177_17562848221082879 – Supplemental material for A single dedicated vaccination visit improves vaccination coverage of patients with inflammatory bowel disease
Supplemental material, sj-tif-2-tag-10.1177_17562848221082879 for A single dedicated vaccination visit improves vaccination coverage of patients with inflammatory bowel disease by Guillaume Le Cosquer, Lionel Grangeon, P
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2020 · Journal Article
Poullenot F, Ollivier J, Rivière P, Sauvaget L, et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2018 · Letter
Poullenot F, Nivet D, Paul S, Riviere P, et al.
Inflammatory bowel diseases · 2016 · Journal Article
Poullenot F, Seksik P, Beaugerie L, Amiot A, et al.
Journal of Crohn's & colitis · 2015 · Clinical Trial
Coutzac C, Chapuis J, Poullenot F, Chabrun E, et al.